Company Profile · Healthcare

DexCom Inc

DXCM · US
Industry
Medical Devices
Exchange
US
Country
USA
IPO date
Apr 14, 2005
Employees
11,000
Website
www.dexcom.com
Current Price
$72.47
Live · Jun 18, 2026
Baillie Growth Score
48/100
Weak
Intrinsic Value · Three-Tier Range Current price $72.47 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $47–$55 / fair $65–$75 / optimistic $90–$100. At $72.47, Within the fair intrinsic-value range.

At publication $71.9 (May 22, 2026)

Research on this stock

No reports on this stock in your language yet.

About the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Financial snapshot
Market cap$27.49B
Revenue (TTM)$4.82B
EBITDA$1.29B
Profit margin19.31%
ROE35.62%
P/E (TTM)30.57
Forward P/E27.86
PEG1.33
EPS$2.33
52-week range$54.11 – $89.98
Analyst target$85.21
Analyst rating4.7 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.